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Effectiveness of a Multidisciplinary
Patient Assistance Program in
Diabetes Care
Doyle E, Taveira T, Julian R, Cohen L, Monteith K

Describing patient health outcomes at the Diabetes
Resource Center at St. Joseph Health Services of
Rhode Island
Background
Presently, there are over 23.6 million Americans with diabetes
mellitus.7 Approximately 65% of people with diabetes mellitus die of
cardiovascular disease,4 which is largely preventable by simultaneous
control of multiple cardiovascular risk factors.5 It is estimated that
nearly 21 million patients with diabetes are uninsured or
underinsured.7 Patient assistance programs have been proposed to be
an effective model to improved diabetes related outcomes through
efficient use of resources, improvement of access to care, intensive
medication up-titration and promotion of behavioral change through
group support.9 However, little is known about the effectiveness of
these types of programs in diabetes care.
Abstract
Objectives: The primary outcome for diabetes analysis is the
change in hemoglobin A1C (HbA1c). This value describes the average
glucose level in a patient’s blood stream over the preceding three
months. Secondary outcomes will be changes in blood pressure, serum
lipids, and patient body mass index.
Study Design: This retrospective chart review is to evaluate the
changes in personal health markers that serve as prognostic indicators
in the progression of type 2 diabetes mellitus.
Methods: Assessing electronic medical records of selected
patients in the DRC database from baseline to a twelve-month followup period can show how effective the Patient Assistance Liaison (PAL)
program is. A statistical analysis of the data will be performed between
the data sets of PAL Program patients and insured (non-PAL) patients
to show significance. It is hoped that the data will serve as pilot data
to determine if a prospective, randomized-controlled study should be
performed to evaluate the efficacy of patient assistance program
strategies in reducing the overall cardiovascular risk of patients with

type 2 diabetes. Subjects in the PAL Program at the Diabetes Resource
Center (DRC) of the St. Joseph Health Services of Rhode Island
Hospital for Specialty Care have no health insurance to pay for needed
services and medications. It is desirable to know if the care they are
receiving is equivalent to patients at the DRC that have prescription
drug insurance from a third party provider.
Results: From baseline to follow-up, the PAL program patients
experienced improvements in health that were equivalent to that of
the non-PAL patient group. In the outcomes of total cholesterol and
low-density lipoprotein cholesterol (LDL-C), the PAL group had
statistically significant improvements that were not seen in the nonPAL group.
Conclusion: If properly managed and funded, a patient
assistance program can be an effective outlet for patients with little or
no resources.

Introduction
The patients seen at the Diabetes Resource Center (DRC) of the St.
Joseph Health Services of Rhode Island are served to prevent
cardiovascular disease and microvascular complications associated
with uncontrolled diabetes and disease progression. It is beneficial to
observe whether having health insurance can cause disparities in
health care delivery at the DRC and influence overall outcomes in longterm disease management. The DRC Patient Assistance Liaison (PAL)
Program enrolls patients without health insurance referred to the
program from the Adult Primary Care clinic in the St. Joseph Health
Services Hospital. The PAL program was initiated in July 2006 and has
continued to grow. To gauge the efforts of the program, an audit was
conducted to assess the health status of the PAL patients.

Research Design and Methods
Study Design:
This was a retrospective chart review of the electronic medical records
of patients diagnosed with type 2 diabetes enrolled at the St. Joseph
Health Services DRC from July 1, 2006 to March 31, 2007. There were
assessments for medical history, systolic blood pressure (SBP),
diastolic blood pressure (DBP), hemoglobin A1c (HbA1c), lipid profile,
body mass index (BMI) and enrollment in the PAL program. This study
resembled a cohort design.
The University of Rhode Island’s Institutional Review Board in
conjunction with the St. Joseph Health Services of Rhode Island
approved this study.

A total of 199 patients were assessed to see if clinical significance
exists in the care provided to the patients served at the DRC. This
care must meet national standards. The American Diabetes
Association, American Heart Association, and the Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure have set the guidelines
employed.
Inclusion Criteria:
All patients eligible for inclusion had to be at least 18 years of age
with a chart documentation of type 2 diabetes mellitus in the St.
Joseph Health Services DRC. Patients must be enrolled between July 1,
2006 and March 31, 2007, and have documented follow-up visits
twelve months after the original enrollment date. Subjects must have
complete lipid profiles, blood pressures, HbA1c values, and body mass
index measurements upon entry into the program and then 12 months
after. Subjects must see a primary care provider at the St. Joseph
Health Services of Rhode Island’s Adult Primary Care clinic and have a
record in the electronic medical system of the DRC database.
Exclusion criteria:
Any patient who does not have baseline values for serum lipids, blood
pressure, HbA1c or body mass index, as well as the corresponding
values 12 months later.

Diabetes Resource Center (DRC) Patients:
Patients are referred to the DRC by primary care physicians in the
Adult Primary Care clinic of the St. Joseph Health Services Hospital for
Specialty Care, by outside primary care physicians or social service
agencies, or are self-referred for case and diabetes management. The
DRC provides access to diabetes education, individualized primary care
visits for diabetes and referral for specialty care services within the
DRC. Specialty care services consist of consultation with Certified
Diabetes
Outpatient
Educator
(CDOE)
nurses,
pharmacists,
nutritionists
or
visits
with
treatment
specialists
such
as
ophthalmologists and podiatrists, as well as enrollment into the PAL
program to obtain free medication for their diabetes and related
conditions.
Patient education consists of six, one hour class sessions consistent
with American Diabetes Association standards for self-management
eduction.6 Visits with a primary care physician are held approximately
every 3-4 months and last approximately 20 minutes. Specialty visits

can last up to one hour in length with the DRC CDOE nurses,
pharmacists, nutritionists, ophthalmologists and podiatrists.

PAL Program:
Patients eligible for the PAL program were uninsured and were unable
to pay for their medications for the treatment of diabetes or diabetesrelated conditions. Under the supervision of a physician, the CDOE
nurses were the primary providers in the DRC. At the initial visit,
nurses assessed medication adherence and laboratory parameters, and
developed a treatment plan to control blood pressure, lipids and
diabetes.
Options for smoking cessation were discussed when
applicable. Individualized diet and exercise programs were also
created, and referral to a nutritionist and physical therapist were made
on an as-needed basis. The Pharm.D. intern assisted with medication
reconciliation and pharmacotherapeutic recommendations for the
treatment of hypertension, hyperlipidemia, diabetes and tobacco
cessation and made recommendations for therapeutic interchange
based on the current availability of free medications in the clinic
supply.

Outcomes:
The primary outcome is the change in HbA1c values, serum lipids and
blood pressures in patients with diabetes enrolled in the PAL Program
at the St. Joseph Health Services of Rhode Island Hospital for Specialty
Care DRC after twelve months of enrollment.
Secondary outcomes include the difference in national guideline
adherence rates for serum lipids1, glycemic control2 and blood
pressure3 between patients who are enrolled and those who are not
enrolled in the PAL program at the St. Joseph Health Services DRC
after twelve months of the patient baseline date. Guideline adherence
at twelve months will be defined as an HbA1c < 7%, SBP < 130mmHg,
DBP <80mmHg, total cholesterol <200mg/dL, LDL-C <100mg/dL,
HDL-C > 40mg/dL, and triglycerides < 150mg/dL. Recommendations
for weight loss were given to all patients in the DRC when applicable. A
successful outcome for BMI would therefore be classified as <
30kg/m2.

Statistical Analysis:
Continuous variables will be expressed as mean ± SD, and categorical
variables as percentages. We will use statistical software (SPSS 9.0 for

Windows; SPSS, Inc., Chicago, Illinois) for data analysis. MANOVA with
repeated measures will be used to compare the serum lipids, glycemic
measures, blood pressure and BMI values at baseline and twelve
months after enrollment in the St. Joseph Health Services DRC in both
those enrolled in the PAL program and those not enrolled. Discriminant
function analysis (DFA) can be used to determine the relationship
between the demographic variables and change in dependent variables
during treatment. Chi-square testing will be used to compare the
frequency of patients that achieved American College of Cardiology /
American Heart Association3 and American Diabetic Association7
guideline recommended goals for the major cardiovascular risk factors
at baseline and twelve months after. In order to detect the apparent
effect of the PAL program vs. those not enrolled in PAL, we will repeat
the above analyses by excluding those patients who were at target
goals for individual risk factors at baseline. In addition, the change in
weight will be reanalyzed in those patients with a baseline BMI >
30kg/m2. Stepwise logistic regression modeling will be used to
determine the predictors of improvement as defined as guideline
adherence when patients met the therapeutic goal of SBP < 130 mm
Hg, A1C < 7%, total cholesterol < 200 mg/dl and LDL Cholesterol <
100 mg/dL. All tests will be considered significant when 2-sided P is
less than 0.05.
Sample size calculations and power analysis:
Based on preliminary data, a sample size of 170 would provide >90%
power to detect a 10% difference between baseline values and 12
months of follow-up in the DRC for each of the individual outcome
measures: serum lipids, glycemic measures, and BMI values with a
type I (alpha) error of <5%. The sample size was increased by 15% to
account for potential missing data given that this was a retrospective
analysis.

Results
Population:
Patient demographics between July 1, 2006 and March 31, 2007

Table 1. Baseline Characteristics (n=199)
Characteristic
PAL Group
Non-PAL
n=93
Group
n=106

P-value

54.1±10.3

57.9±10.9

0.01

41.8

41.0

1.0

15.2
64.1
15.2
5.4

5.7
77.1
11.4
5.7

0.03
0.06
0.06
0.93

33.0±7.1

33.3±6.8

0.81

Hypertension

61.3

67.9

0.37

Hyperlipidemia
Microvascular
Complications
Neuropathy
Nephropathy
Retinopathy
Smoking Cessation

63.4

47.2

0.02

12.0
4.4
5.4
2.2

21.9
11.4
3.0
3.8

0.09
0.11
0.48
0.69

Medication Utilization
Sulfonylurea
Metformin
Thiazolidinedione
Insulin
Aspirin
ACE-Inhibitor
Lipid Agent

10.9
10.9
7.6
4.4
5.4
6.5
4.4

15.2
10.5
17.3
5.7
13.6
16.2
11.4

0.41
1.0
0.05
0.75
0.002
0.04
0.11

Age (Years)
Male
Ethnicity
White
Hispanic
Black
Asian
Body Mass Index
(kg/m2)

Patients were similar at baseline from what the data indicate.
Significance only existed for age, the white ethnicity, hyperlipidemia,
aspirin and ACE-Inhibitor use. It is possible that more people were
taking aspirin than as indicated here since it is easily available overthe-counter.

Twelve-month follow up in HbA1c were similar for the PAL and nonPAL groups (8.1±1.9% v 8.1±2.0%, p=0.98), respectively. Total
cholesterol values were statistically significant at baseline for the PALgroup and the non-PAL group (184.2±37.5 v 167.2±39.9, p=0.0022),
respectively, but were not statistically significant at the twelve-month
follow-up period (169.3±36.7 v 169.9±44.6, p=0.9179). LDL-C values

were significantly different at baseline for the PAL group and the nonPAL group (110.1±34.1 v 97.4±33.5, p=0.0089), respectively. There
was however, no difference at the twelve-month follow-up period
(97.3±31.6 v 102.3±38.3, p=0.3227). BMI values were not different
at baseline or follow-up for the PAL group and the non-PAL group
(32.8±7.0 v 33.3±6.8, p=0.6697) and (34.0±7.1 v 33.3±6.2,
p=0.6126), respectively (Table 2).
Both PAL and non-PAL patients had similar adherence to guideline
standards in the HbA1c values. At enrollment, 34.41% of PAL patients
were at goal compared to 33.02% of non-PAL patients. At follow-up
twelve months later, 35.48% of PAL patients were at goal, compared
to 30.19% of non-PAL patients. There exists no statistical significance
between these two groups in HbA1c values at follow-up (P=0.88).
Significance did exist in the LDL-C values at baseline as 36.56% of PAL
patients were at goal, compared to 52.83% of non-PAL patients
(P=0.02). No statistical significance existed between the two groups at
the follow-up period. There were 63.04% of PAL patients at goal,
compared with 52.83% of non-PAL patients (P=0.15) (Figure 2).

Discussion
These data demonstrate that patients enrolled into a patient assistance
program are able to achieve a similar level of HbA1c, blood pressure,
lipids and BMI as insured patients. In the PAL Program, all patients
were receiving the same standards of care, were given the same
weight loss, blood pressure and lipid goals, reduction strategies, and
received similar care for diabetes. Despite the similarities at baseline,
and the equality of care provided to all patients, it appears that the
PAL program patients experienced some significant reductions in
cardiovascular risk that were not witnessed to the same extent for the
patients not in the PAL group.
The effectiveness of the multidisciplinary patient assistance model as
assessed by changes in guideline adherences at the 12-month followup show that significant progress can be made in individual patient
health. Patients in the PAL program often started out below standard
guidelines and experienced improvements in health that met national
guidelines and were comparable to the non-PAL group.
This is
attributed to increased access to care and free medications provided
by grants and samples from pharmaceutical corporations. This is
encouraging as patient assistance programs are often difficult to enroll

in, and can still end up draining a patient’s financial resources. From
the guideline adherence rates and actual patient values, having health
insurance did not cause disparities in patient health.
This is important because many patient assistance programs exist but
there is little data substantiating their effectiveness.
Intriguing are the trends of the HbA1c values over the 12-month
duration for the separate categories. While the non-PAL patient values
went up, the average values for the PAL program patients decreased
from baseline. As diabetes care is a primary concern for the DRC, and
diabetes itself is an independent cardiovascular risk factor, guidelines
recommend tight blood glucose control to maintain overall health.
Other important improvements occurred in HbA1c values. Although
some patients, particularly in the PAL program, did not achieve a value
under 7%, there were still significant reductions. Many patients had
poor disease control before entrance into the program. Some patients
started at HbA1c values over 12%, and achieved a value under 10%.
This would still qualify as a positive difference, and this is important
for a patient to know.
For this analysis, we employed national
guidelines, and further information about all patients that had HbA1c
values
decline
is
not
provided
in
this
discussion.
Most notable are the results from the LDL-C, triglyceride and total
cholesterol analyses. Patients in the PAL program achieved a
statistically significant reduction while the majority of insured patients
stayed the same or worsened. The lipid values are broken up into total
and LDL cholesterol values, which are the two main independent risk
factors for atherosclerotic vascular events in diabetic patients. In the
LDL-C category, the PAL group had a statistically significant reduction,
which is demonstrated by the guideline adherence rate and the
comparative analysis with the non-PAL group. Triglycerides are
important to assess as well since they serve as an objective measure
of circulating fatty acids. While the non-PAL patients had slightly
better outcomes in triglycerides, the differences are not statistically
significant.
Study limitations include a single site program. Nonetheless the results
demonstrate the effectiveness of a PAL program to manage a
population with multiple comorbidities that traditionally is considered
difficult to treat. A second limitation is that there is only a twelvemonth follow-up period, and it is difficult to know if effectiveness can
be maintained over longer periods of time. Third, given the training
and experience of the PAL providers, it is uncertain whether the
success of this model can be easily reproduced through another PAL

team with different training and experience. Further, randomizedcontrolled trials with a different team of providers of different
experiences and in other institutions would be necessary to assess the
generalizability of the PAL model. Finally, there is no cost-assessment
of the PAL Program, as costs were not formally tracked. However, a
simple cost estimation associated with the program can be attempted
by including personnel salaries, facility costs, medication supplies, and
laboratory costs per participant. The cost for the personnel in this
program was calculated using the hourly rate for time required by each
provider for preparation, intervention and documentation. The hourly
rate was calculated using the annual salaries of providers from the
official job site for the United States Federal Government
(www.usajobs.gov) by July, 2008. Facility costs were estimated by
including the cost for support staff, space, electricity, mail, fax and
telephones. Laboratory costs included the cost for a chem-7, lipid
panel and HbA1c tests ordered at baseline and 12-month follow-up.
These added for a total of $49.23 per patient per hour. It is reasonable
to assume that the control of cardiovascular risk factors may reduce
long-term costs via reduction of acute care visits, hospitalization and
diabetes related complications.

Conclusion:
This study suggests that a PAL program model is feasible and effective
for improving multiple cardiac risk factors in patients with type 2
diabetes.

Appendix:
Figure 1. Patient Selection

Total Adult Primary Care
Clinic Registries
n=6020

Active Diagnosis of
Diabetes Mellitus Type 2
n=373

Citations of Diabetic
Patients Without Health
Insurance
n=131

Citations of Diabetic
Patients With Health
Insurance
n=242

Patients with Record of
Office Visit 12 Months
After Enrollment Date
n=93

Patients with Record of
Office Visit 12 months
After Baseline Date
n=106

Table 2. Baseline to Follow-Up Value and Average Change
P-value for Total Cholesterol Parameter=0.0023
P-value for LDL-C Parameter=0.0015
PAL Group

Non-PAL
Group

N=93
Parameters

Baseline

N=106
12 Months

Average

Baseline

12 Months

Change
HbA1c (%± SD)

Average
Change

8.3 ± 2.2

8.1 ± 1.9

-0.2 ± 1.7

8.2 ± 2.0

8.1 ±2.0

-0.1 ± 1.4

136.7 ± 21.1

133.6 ± 17.1

-3.3 ± 20.7

139.1 ± 20.1

134.3 ±

-4.8 ± 22.2

SBP (mmHg ± SD)

20.7
81.3 ± 10.9

78.7 ± 9.2

-2.5 ± 11.1

79.4 ± 11.0

77.1 ± 10.4

-2.3 ± 12.7

184.2 ± 37.5

169.3 ± 36.7

-15.7 ± 45.3*

167.2 ± 39.9

169.9 ±

2.7 ± 37.7

DBP (mmHg ± SD)

Total Cholesterol
(mg/dL± SD)
LDL-C (mg/dL± SD)

44.6
110.1 ± 34.1

97.3 ± 31.6

-13.4 ± 41.9*

97.4 ± 33.5

102.3 ±

4.9 ± 37.2

38.3
HDL-C (mg/dL ± SD)

Triglycerides

45.6 ± 12.4

44.8 ± 12.1

-0.7 ± 12.2

45.0 ± 13.9

42.0 ± 12.0

-3.0 ± 12.5

145.9 ± 104.8

128.9 ± 74.9

-18.2 ± 109.4

122.2 ± 72.8

128.7 ±

6.5 ± 68.0

(mg/dL ± SD)
BMI (kg/m2 ± SD)

73.1
32.8 ± 7.0

34.0 ± 7.1

1.1 ± 4.3

33.3 ± 6.8

33.3 ± 6.2

0.2 ± 2.7

Figure 2. Guideline Adherence of Baseline and Follow-Up Analysis
Guideline Adherence in Hemoglobin A1c
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